BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18472616)

  • 1. Management of patients with resistant or refractory chronic myelogenous leukemia.
    Quintás-Cardama A; Cortes J
    Oncology (Williston Park); 2008 Apr; 22(4):430-7; discussion 437, 442, 446 passim. PubMed ID: 18472616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
    Thienelt CD; Green K; Bowles DW
    Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
    Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
    J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
    Kimura S
    Rinsho Ketsueki; 2009 Jul; 50(7):547-55. PubMed ID: 19638722
    [No Abstract]   [Full Text] [Related]  

  • 6. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
    Jabbour E; Kantarjian H; Cortes J
    Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinase inhibitors in chronic myelogenous leukemia.
    Quintás-Cardama A; Cortes J
    Clin Adv Hematol Oncol; 2006 May; 4(5):365-74. PubMed ID: 16728945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing tolerability of TKI therapy in CML.
    Hochhaus A
    Blood; 2014 Feb; 123(9):1284-5. PubMed ID: 24578491
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
    Cortes JE; Kantarjian HM; Brümmendorf TH; Kim DW; Turkina AG; Shen ZX; Pasquini R; Khoury HJ; Arkin S; Volkert A; Besson N; Abbas R; Wang J; Leip E; Gambacorti-Passerini C
    Blood; 2011 Oct; 118(17):4567-76. PubMed ID: 21865346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
    Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
    Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
    Okimoto RA; Van Etten RA
    Curr Opin Hematol; 2011 Mar; 18(2):89-97. PubMed ID: 21252655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
    Li J; Xu G; Yu S; He L; Guo L
    J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Drugs Today (Barc); 2012 Mar; 48(3):177-88. PubMed ID: 22462037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted drugs in chronic myeloid leukemia.
    Gora-Tybor J; Robak T
    Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
    Holstein SA; Stokes JB; Hohl RJ
    Leuk Res; 2009 Feb; 33(2):344-7. PubMed ID: 18835038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
    Jabbour E; Cortes J; O'Brien S; Giles F; Kantarjian H
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S25-31. PubMed ID: 17292738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors: the first decade.
    Agrawal M; Garg RJ; Cortes J; Quintás-Cardama A
    Curr Hematol Malig Rep; 2010 Apr; 5(2):70-80. PubMed ID: 20425399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.